Shalby Ltd - 540797 - Disclosure Under Regulation 7(2)(B) Of SEBI (Prohibition Of Insider Trading) Regulations. 2015.
Acquisition of 700,000 equity shares of Company by Shalby Limited Employees Welfare Trust31-05-2022
31-05-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for quarter and year ended March 31, 2022.30-05-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Conference call to discuss Audited Financial Results for quarter and year ended March 31, 2022 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201528-05-2022
Shalby Ltd - 540797 - Compliances-Reg.24(A)-Annual Secretarial Compliance
for year ended March 31, 202228-05-2022
Q4FY22 Quarterly Result Announced for Shalby Ltd.
Healthcare Facilities firm Shalby declares Q4FY22 result: Hospital Performance Highlights: FY2022 vs FY2021 Total Revenues of Rs. 6,598 million, growth of 54% YoY Operating EBITDA of Rs. 1,426 million with EBITDA margins of 22% Profit After Tax was Rs. 698 million, growth of 63% YoY Realized Return on Capital Employed improved to 14%, compared to 8% in FY21 Bed occupied during the quarter were 563, with occupancy rate of 46% In patients count of 40,603, growth of 41% YoY Total Surgery count of 20,240, growth of 70% YoY Hospital Performance Highlights: Q4 FY2022 vs Q4 FY2021 Total Revenues of Rs. 1,523 million, growth of 6% YoY Operating EBITDA of Rs. 323 million with EBITDA margins of 21% Profit After Tax was Rs. 157 million, growth of 42% YoY Bed occupied during the quarter were 499, with occupancy rate of 42% In patients count of 9,629, growth of 11% YoY Total Surgery count of 5,558, growth of 1.6% YoY Mr. Shanay Shah, President said: “Shalby delivered a strong performance during the year and I am pleased that Shalby as a hospital group was able to support the Covid-19 patients especially during the second wave of Covid-19 which impacted the lives of many. In the second half of the year, we saw a strong recovery of elective surgeries which continues to drive our core specialty revenues. During the year, a total of 20,240 elective surgeries were performed, an increase of 70% on YoY basis. We saw a strong jump of 41% for in-patient count and travel of international patients has also resumed. Occupied beds increased to 563 up by 31% in FY22 from 428 occupied beds in FY21. ARPOB and ALOS were recorded at Rs. 33,707 and 4.55 days in FY22 vis-a-vis Rs. 27,400 and 5.42 days in FY21. Our core specialty such as Arthroplasty, Critical care & General Medicine, Oncology, Cardiac Science, Orthopaedic, Neurology and Nephrology contributed 29%, 22%, 9%, 8%, 8%, 5% and 3% to the revenues respectively. Continued generation of strong cash flow from hospital operation of Rs. 1,238 million helped to strengthen our balance sheet further. Our Realized Return on Capital Employed has increased from 8% in FY21 to 14% in FY22. We have closed the year with a net cash balance of Rs. 475 million at group level and are well positioned to fund our strategic growth plans. Shalby has evolved and become a true multi-specialty hospital group which is backed by clinical excellence and patient delight. Shalby Jaipur created history with 200 Joint Replacement surgeries in a month by a single Orthopedic surgeon. We at Shalby units, have successfully completed total 28 Kidney and Liver transplants in FY22. We continue to focus improving internal systems and processes. We have also successfully implemented SAP in February 2022 and this strategic implementation aims to strengthen our financial & operational processes by improvising database management, administration, security, real-time access and advance analytics to support the business decisions.” Result PDF26-05-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
for Audited Financials for FY 2021-2226-05-2022
Shalby Ltd - 540797 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper publication of audited Financial Results (Standalone and Consolidated) for quarter and year ended March 31, 202~ - Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 201526-05-2022
Shalby Ltd - 540797 - Corporate Action-Board approves Dividend
Shalby Board recommend dividend of Rs. 1.00 per equity share of Rs. 10.0025-05-2022